{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:18:15Z","timestamp":1793308695055,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Domestic Animal Endocrinology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.domaniend.2011.03.001","type":"journal-article","created":{"date-parts":[[2011,4,7]],"date-time":"2011-04-07T10:32:12Z","timestamp":1302172332000},"page":"42-49","source":"Crossref","is-referenced-by-count":36,"title":["The GLP-1 mimetic exenatide potentiates insulin secretion in healthy cats"],"prefix":"10.1016","volume":"41","author":[{"given":"C.","family":"Gilor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.K.","family":"Graves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gilor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.K.","family":"Ridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.domaniend.2011.03.001_bib1","series-title":"Textbook of Veterinary Internal Medicine - Diseases of the Dog and Cat","first-page":"1563","article-title":"Diabetes Mellitus","author":"Nelson","year":"2005"},{"key":"10.1016\/j.domaniend.2011.03.001_bib2","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1210\/jcem-25-10-1317","article-title":"Intestinal factors in the control of insulin secretion","volume":"25","author":"McIntyre","year":"1965","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.domaniend.2011.03.001_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.mce.2008.08.012","article-title":"The incretin system and its role in type 2 diabetes mellitus","volume":"297","author":"Holst","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.domaniend.2011.03.001_bib4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.domaniend.2011.03.001_bib5","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1210\/jc.86.8.3717","article-title":"Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients","volume":"86","author":"Toft-Nielsen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.domaniend.2011.03.001_bib6","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1210\/jc.86.8.3853","article-title":"Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes","volume":"86","author":"Toft-Nielsen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.domaniend.2011.03.001_bib7","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.domaniend.2011.03.001_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.regpep.2004.06.007","article-title":"What do we know about the secretion and degradation of incretin hormones?","volume":"128","author":"Deacon","year":"2005","journal-title":"Regul Pept"},{"key":"10.1016\/j.domaniend.2011.03.001_bib9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ajhp\/62.2.173","article-title":"Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus","volume":"62","author":"Kolterman","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.domaniend.2011.03.001_bib10","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.298.2.194","article-title":"Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis","volume":"298","author":"Amori","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.domaniend.2011.03.001_bib11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-143-8-200510180-00006","article-title":"Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial","volume":"143","author":"Heine","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.domaniend.2011.03.001_bib12","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.clinthera.2007.11.006","article-title":"Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial","volume":"29","author":"Barnett","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.domaniend.2011.03.001_bib13","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1185\/030079908X260862","article-title":"Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis","volume":"24","author":"Glass","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.domaniend.2011.03.001_bib14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clinthera.2007.01.015","article-title":"Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials","volume":"29","author":"Buse","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.domaniend.2011.03.001_bib15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/01.tp.0000251379.46596.2d","article-title":"Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes","volume":"83","author":"Ghofaili","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.domaniend.2011.03.001_bib16","doi-asserted-by":"crossref","first-page":"2072S","DOI":"10.1093\/jn\/134.8.2072S","article-title":"Canine and feline diabetes mellitus: nature or nurture?","volume":"134","author":"Rand","year":"2004","journal-title":"J Nutr"},{"key":"10.1016\/j.domaniend.2011.03.001_bib17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.domaniend.2009.08.004","article-title":"Oral glucose leads to a differential response in glucose, insulin, and GLP-1 in lean versus obese cats","volume":"38","author":"Hoenig","year":"2010","journal-title":"Domest Anim Endocrinol"},{"key":"10.1016\/j.domaniend.2011.03.001_bib18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.tvjl.2008.11.017","article-title":"The dipeptidyl peptidase IV inhibitor NVP-DPP728 reduces plasma glucagon concentration in cats","volume":"183","author":"Furrer","year":"2010","journal-title":"Vet J"},{"key":"10.1016\/j.domaniend.2011.03.001_bib19","unstructured":"Gilor C, Graves TK, Gilor S, Ridge TK, Weng H, Dossin O. The incretin effect in cats: comparison between oral glucose, lipids and amino acids. Domest Anim Endocrinol, in press."},{"key":"10.1016\/j.domaniend.2011.03.001_bib20","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/j.1939-1676.2010.0544.x","article-title":"Pharmacodynamics of insulin detemir and insulin glargine assessed using an isoglycemic clamp method in healthy cats","volume":"24","author":"Gilor","year":"2010","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.domaniend.2011.03.001_bib21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1053\/meta.2001.22519","article-title":"Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro","volume":"50","author":"Parkes","year":"2001","journal-title":"Metabolism"},{"key":"10.1016\/j.domaniend.2011.03.001_bib22","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1042\/CS19980050","article-title":"Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects","volume":"95","author":"Edwards","year":"1998","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.domaniend.2011.03.001_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ijpharm.2008.01.015","article-title":"Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration","volume":"356","author":"Gedulin","year":"2008","journal-title":"Int J Pharm"},{"key":"10.1016\/j.domaniend.2011.03.001_bib24","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1124\/pr.108.000604","article-title":"The role of incretins in glucose homeostasis and diabetes treatment","volume":"60","author":"Kim","year":"2008","journal-title":"Pharmacol Rev"},{"issue":"5","key":"10.1016\/j.domaniend.2011.03.001_bib25","doi-asserted-by":"crossref","first-page":"E1088","DOI":"10.1152\/ajpendo.00464.2009","article-title":"Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system","volume":"298","author":"Perez-Tilve","year":"2010","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.domaniend.2011.03.001_bib26","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1369\/jhc.2008.951319","article-title":"Expression of the GLP-1 receptor in mouse, rat, and human pancreas","volume":"56","author":"Tornehave","year":"2008","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.domaniend.2011.03.001_bib27","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1055\/s-2005-837526","article-title":"The recombinant rat glucagon-like peptide-1 receptor, expressed in an alpha cell line, is coupled to adenylyl cyclase activation and intracellular calcium release","volume":"113","author":"Dillon","year":"2005","journal-title":"Exp Clin Endocrinol Diabetes"}],"container-title":["Domestic Animal Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0739724011000312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0739724011000312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,9]],"date-time":"2019-06-09T16:24:11Z","timestamp":1560097451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0739724011000312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0739724011000312"],"URL":"https:\/\/doi.org\/10.1016\/j.domaniend.2011.03.001","relation":{},"ISSN":["0739-7240"],"issn-type":[{"value":"0739-7240","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}